We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Vericel Corp (VCEL) Common Stock NPV

Sell:$54.50 Buy:$64.25 Change: $0.55 (0.96%)
Market closed |  Prices as at close on 21 November 2024 | Switch to live prices |
Sell:$54.50
Buy:$64.25
Change: $0.55 (0.96%)
Market closed |  Prices as at close on 21 November 2024 | Switch to live prices |
Sell:$54.50
Buy:$64.25
Change: $0.55 (0.96%)
Market closed |  Prices as at close on 21 November 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Vericel Corporation is a fully-integrated, commercial-stage biopharmaceutical company. The Company is a provider of advanced therapies for the sports medicine and severe burn care markets. It markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous-cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. The Company also holds a license for North American rights to NexoBrid (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for the removal of eschar in adults with deep partial-thickness and/or full-thickness burns.

Contact details

Address:
64 Sidney St
CAMBRIDGE
02139
United States
Telephone:
+1 (734) 9305555
Website:
https://vcel.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
VCEL
ISIN:
US92346J1088
Market cap:
$2.76 billion
Shares in issue:
49.36 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Dominick Colangelo
    President, Chief Executive Officer, Director
  • Joseph Mara
    Chief Financial Officer
  • Michael Halpin
    Chief Operating Officer
  • Karen Mahoney
    Chief Human Resource Officer
  • Sean Flynn
    Senior Vice President, General Counsel, Secretary
  • Jonathan Hopper
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.